Results

1–10 of 12 results for Age related macular degeneration

Safety Profiles of Combined Anticomplement and Anti-VEGF Intravitreal Therapies for Age-Related MacularDegeneration From Real-World Data
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2025
Complement Inhibition Treatment for Geographic Atrophy in Eyes With Exudative AMD
Josh Wallsh
Annual Meeting Talks
2025
Baseline Characteristics Associated With Catastrophic Vision Loss Due to Subretinal Hemorrhage in Patients Undergoing Treatment for Neovascular Macular Degeneration
Eric W Schneider, MD
Annual Meeting Talks
2024
Preservation of Vision by ANX007: Clinical Results and Anatomic Changes From the Phase 2 ARCHER Trial
Joel Pearlman, MD, PhD
Annual Meeting Talks
2024
Pooled Safety Analysis and Immunogenicity of a Single Intravitreal Injection of JNJ-1887 (Gene Therapy, AAVCAGsCD59) in Patients With AMD
Christine Kay, MD
Annual Meeting Talks
2024
Results From Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD
Annual Meeting Talks
2024
Analysis of the Long-term Visual Outcomes of ForeseeHome Remote Telemonitoring.
Michael J. Elman, MD
Annual Meeting Talks
2022
Evaluating ANX007, a Novel C1q Inhibitor, in the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration: The ARCHER Study
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2021
Clinical and Demographic Factors Associated With Loss to Follow-up in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Durga Borkar, MD
Annual Meeting Talks
2021
Impact of Baseline Imbalances on the Efficacy of Pegcetacoplan for the Treatment of GA: A Post Hoc Analysis of OAKS, DERBY, and FILLY
Sunir J. Garg, MD, FACS, FASRS
Updates from the Field
2022